FENTANYL PATCH
Clinical Criteria Summary
Patient Eligibility & Indications
- Requires around-the-clock analgesia for moderate to severe, persistent chronic pain
- Must be opioid-tolerant: taking ≥60 mg oral morphine daily, ≥20 mg oral methadone daily, ≥30 mg oral oxycodone daily, ≥8 mg oral hydromorphone daily, or an equianalgesic dose of another opioid for ≥1 week
- Must meet at least one condition: unable to swallow/tolerate/absorb oral preparations; unable to adhere to oral opioid regimen due to cognitive/psychiatric impairment; requires chronic/stable pain management as part of end-of-life care where twice-daily or more frequent oral administration is problematic; or documented current/past history of intolerable adverse effects to long-acting morphine and oxycodone (e.g., constipation unresponsive to aggressive laxatives, nausea inadequately controlled by antiemetics/dose titration)
- Applies to new starts only; stable patients should not be required to discontinue unless clinically indicated
Exclusion Criteria
- Mild pain
- Breakthrough or intermittent pain (as-needed/p.r.n. analgesia)
- Postoperative pain, including outpatient or day surgeries
- Pain due to acute clinical conditions/situations (e.g., acute trauma, new onset herpes zoster/shingles)
- Hypersensitivity to fentanyl or local hypersensitivity reaction not adequately controlled with topical medications
- Contraindication to opioids (significant respiratory depression, acute/severe bronchial asthma/hypercarbia, known/suspected paralytic ileus)
Dosing & Administration Requirements
- Initial dose is an initial conversion dose; must be individualized based on medical condition, potency/dose/type of previous opioid, degree of tolerance/exposure, past analgesic response/adverse experiences, and accuracy of conversion factors
- Conversion table is unidirectional (other opioids TO transdermal fentanyl only); do not use to convert FROM transdermal fentanyl to other opioids due to risk of overdose/toxicity
- Dose increases generally should not be sooner than 3 days after initial dose or more frequently than every 6 days thereafter
- Dosage increments based on daily supplemental opioid use: morphine 45 mg/d orally equals a 12 mcg/h increase in transdermal fentanyl dose
- Patches may be applied every 48 hours instead of 72 hours for some patients; evaluate dose increase before changing interval to maintain 72-hour regimen
- Short-acting analgesics should be provided on an as-needed basis until sufficient analgesic effects are achieved (1–2 days) and considered for predictable, incident breakthrough pain
- Patches available in strengths: 12.5, 25, 50, 75, 100 mcg/h
- Do not cut, damage, or alter patches prior to application; use alternate opioid therapy if fractions are needed
- Remove previous patch before applying next dose (especially in inpatient settings); check skin folds
- Avoid external heat on patch site (heating pads, electric blankets, saunas, hot tubs, heated water beds, hot baths, sunbathing); monitor for toxicity if fever/increased core temperature develops
- Remove patch prior to MRI; replace after procedure
Safety Monitoring & Risk Mitigation
- Verify doses during medication reconciliation for hospitalized patients using patches at home
- Implement risk mitigation strategies per VA/DOD Clinical Practice Guideline on Management of Opioid Therapy for Chronic Pain (2017): informed consent conversation, ongoing random urine drug testing with confirmatory testing, checking state prescription drug monitoring programs, monitoring for overdose potential and suicidality, providing overdose education, prescribing naloxone rescue with education
- Assess concomitant use of other opioids to reduce overdose risk
- Reduce dose of fentanyl or CNS depressants when used concomitantly; VA/DOD guideline recommends against concurrent use of opioids and benzodiazepines; consider tapering one or both if risks exceed benefits and obtain specialty consultation
- Use caution with concomitant CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, nefazodone, ritonavir, troleandomycin); monitor carefully for extended period and adjust dosage if warranted
- Allow adequate time for recovery from toxicity; monitor and treat for at least 24 hours after patch removal due to mean elimination half-life of 17 hours
- Provide and document mandatory patient/caregiver education on use, indications, high potency, dose, safety precautions, application/removal/disposal, signs of toxicity, secure storage (locked place, out of reach of children/pets), risk of fatal respiratory depression from used patches, and avoiding application in front of children
Special Populations & Precautions
- Elderly, cachectic, or debilitated patients: use caution due to altered pharmacokinetics (poor fat stores, muscle wasting, altered clearance)
- Pregnant women: Pregnancy Category C; use only if potential benefit justifies potential risk to fetus. Not recommended for analgesia during labor and delivery
- Lactating women: Not recommended due to potential risks to infants
Provider Management & Follow-up
- Initiation and adjustments restricted to Pain Clinic, Addiction Medicine, Addiction Psychiatry Specialists with pain management expertise, Oncology (for advanced cancer pain), Hospice and Palliative Specialty Care, or consultation with a practitioner having relevant knowledge/expertise (e.g., CARA mandated Pain Team, local facility-designated pain SME, Pain Clinic providers, Clinical Pharmacy Specialist with pain management scope)
- Patient must be followed by a VA or VA-contracted provider for management of transdermal fentanyl therapy
- For doses >50 mcg/h: evaluate by specialist in pain management, anesthesiology, palliative care, or hematology/oncology
- Perioperative use: Pain experts suggest continuing patch throughout perioperative period to avoid withdrawal or uncontrolled post-op pain; abrupt discontinuation not recommended
- Provider initiation/continuation follows VA/DOD guideline against initiating long-term opioid therapy for chronic pain; ongoing risk mitigation, assessment for OUD, and tapering when risks exceed benefits
- Tapering: Screen/treat complicating conditions first (mental health disorders, OUD/SUD, medical complications, sleep disorders). Dose reductions typically 5% to 20% every 4 weeks
- OUD management: If suspected, refer to addiction-focused medical management in PACT or Interdisciplinary Pain Management Team with Addiction Medicine expertise/MAT access, or Primary Care Mental Health/specialty care
Transitioning Veteran Provision
- If transitioning care from DoD to VHA and VA prescriber determines continuing medication is safe/clinically appropriate after assessment/consultation, the remainder of criteria does not apply